A practical reference on gastric juice protein: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-13. Anything still debated is marked as such rather than presented as settled.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
=== Cinematography === Ricoh GR digital cameras, a series of digital cameras manufactured by Ricoh Ricoh GR (large sensor compact camera), the current line of cameras in the GR series Golmaal Returns, a Hindi comedy film Generator Rex, an animated sci-fi series Guilty Remnant, a fictional cult in The Leftovers (TV series)
Formation of a secondary structure is the first step in the folding process that a protein takes to assume its native structure. Characteristic of secondary structure are the structures known as alpha helices and beta sheets that fold rapidly because they are stabilized by intramolecular hydrogen bonds, as was first characterized by Linus Pauling. Formation of intramolecular hydrogen bonds provides another important contribution to protein stability. α-helices are formed by hydrogen bonding of the backbone to form a spiral shape (refer to figure on the right). The β pleated sheet is a structure that forms with the backbone bending over itself to form the hydrogen bonds (as displayed in the figure to the left). The hydrogen bonds are between the amide hydrogen and carbonyl oxygen of the peptide bond. There exists anti-parallel β pleated sheets and parallel β pleated sheets where the stability of the hydrogen bonds is stronger in the anti-parallel β sheet as it hydrogen bonds with the ideal 180 degree angle compared to the slanted hydrogen bonds formed by parallel sheets.
Bush then issued a statement saying that while Trump was within his rights to call for recounts, he believed the election was "fundamentally fair" and that "its outcome is clear", and said he would offer Biden "my prayers for his success, and my pledge to help in any way I can", as he had for Trump and Obama.
Sources: en.wikipedia.org
=== Environment === Viral proteins, engulfed molecules, or degraded self-structures may initiate autoimmunity via molecular mimicry. This may increase the chances of developing Sjögren's disease. Epstein–Barr virus, hepatitis C, and human T-cell leukemia virus-1 are among the most studied infectious agents in Sjögren's disease. To date, no direct cause-and-effect relationship has been identified between these pathogens and the development of Sjögren's disease. Damaged self-structures targeted for apoptosis may be mistakenly exposed to the immune system, triggering autoimmunity in exocrine glands, which are often prone to autoimmune responses.
After 30 days, photosynthetic efficiency dropped by 85% in UV-exposed samples and 46% in non-UV-exposed samples. However, within 24 hours of returning to Earth-like conditions, photosynthesis began recovering, demonstrating X. parietina's ability to repair its photosynthetic system after prolonged extreme exposure. Recovery appears to be linked to antioxidant production. Under Mars-like conditions, oxidative stress increased antioxidant levels, protecting against UV and temperature fluctuations. Over 30 days, antioxidant levels declined as the lichen neutralized reactive oxygen species (ROS), indicating an adaptive response that supports survival in extreme environments. X. parietina minimizes metabolism under extreme conditions. In the Mars simulation study, photosystem II efficiency declined under UV stress but remained active. UV-shielded samples performed better, suggesting that without radiation exposure, X. parietina could survive Mars-like cold and low pressure. Raman spectroscopy revealed carotenoid and parietin degradation after prolonged UV exposure, but enough pigment remained to protect vital cells, leaving the lichen's structure intact.
== Etymology == The genus name is from Late Latin falco meaning "falcon". The specific epithet sparverius is Medieval Latin for a "sparrowhawk". Until the sixth edition of the AOU Checklist of North American Birds was published by the American Ornithologists' Union in 1983, the most commonly used name for the American kestrel was the sparrow hawk. This was due to a mistaken connection with the Eurasian sparrowhawk in the genus Accipiter. The sixth edition of the AOU Checklist corrected this, officially renaming the bird American kestrel. Several other colloquial names for the kestrel are also in use, including grasshopper hawk, due to its diet, and killy hawk, due to its distinct call.
Sources: en.wikipedia.org
== Further reading == Robert J. Silva: Fermium, Mendelevium, Nobelium, and Lawrencium, in: Lester R. Morss, Norman M. Edelstein, Jean Fuger (Hrsg.): The Chemistry of the Actinide and Transactinide Elements, Springer, Dordrecht 2006; ISBN 1-4020-3555-1, p. 1621–1651; doi:10.1007/1-4020-3598-5_13. Seaborg, Glenn T. (ed.) (1978) Proceedings of the Symposium Commemorating the 25th Anniversary of Elements 99 and 100, 23 January 1978, Report LBL-7701 Gmelins Handbuch der anorganischen Chemie, System Nr. 71, Transurane: Teil A 1 II, p. 19–20; Teil A 2, p. 47; Teil B 1, p. 84.
Things like ideologies, law, government, money and the economy are built on language; they exist because there are stories that billions of people believe. The current prevalence of misinformation suggests that an AI could use language to convince people to believe anything, even to take actions that are destructive. Geoffrey Hinton said in 2025 that modern AI is particularly "good at persuasion" and getting better all the time. He asks, "Suppose you wanted to invade the capital of the US. Do you have to go there and do it yourself? No. You just have to be good at persuasion." The opinions amongst experts and industry insiders are mixed, with sizeable fractions both concerned and unconcerned by risk from eventual superintelligent AI. Personalities such as Stephen Hawking, Bill Gates, and Elon Musk, as well as AI pioneers such as Geoffrey Hinton, Yoshua Bengio, Stuart Russell, Demis Hassabis, and Sam Altman, have expressed concerns about existential risk from AI. In May 2023, Geoffrey Hinton announced his resignation from Google in order to be able to "freely speak out about the risks of AI" without "considering how this impacts Google". He notably mentioned risks of an AI takeover, and stressed that in order to avoid the worst outcomes, establishing safety guidelines will require cooperation among those competing in use of AI. In 2023, many leading AI experts endorsed the joint statement that "Mitigating the risk of extinction from AI should be a global priority alongside other societal-scale risks such as pandemics and nuclear war".
=== Television === Mogo appears in the Batman: The Brave and the Bold episode "The Eyes of Despero!". Mogo appears in Green Lantern: The Animated Series, voiced by Kevin Michael Richardson. Mogo appears in the Mad segment "Does Someone Have to GOa?", voiced by Fred Tatasciore. Mogo and his debut story are referenced in the DC Universe series Lanterns, with Hal Jordan's vault being activated with the voice password "Mogo doesn't socialize".
== In popular culture == In Agatha Christie's 1937 mystery Cards on the Table, Hexobarbital is used in conjunction with Veronal to induce overdose. It is referred to by Hercule Poirot as both N-methyl-cyclo-hexenyl-methyl-malonyl urea and Evipan. It was also used in Graham Greene's The Heart of the Matter (1948) Evipan was prescribed for a main character in tablet form to use as a sleeping aid.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.